Physician profile
Blake Anthony Menchaca
NPI 1699217547
$3,164.52
in general payments reported to CMS, 2019-2025
18 companies · $756 in 2025
The $756 reported for 2025 was more than what 83% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $171 · 2023: $1,165 · 2024: $1,073 · 2025: $756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,993.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $468.20 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $318.50 | 2023-2024 | Andexxa |
| Actelion Pharmaceuticals US, INC. | $250.18 | 2023-2024 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $248.80 | 2025 | Zerbaxa |
| La Jolla Pharmaceutical Company | $243.68 | 2024-2025 | Zevtera, Giapreza |
| Mallinckrodt Hospital Products INC. | $235.91 | 2023-2025 | Terlivaz |
| Inspire Medical Systems, INC. | $228.40 | 2023-2024 | Inspire |
| Astellas Pharma US INC | $211.11 | 2023 | Cresemba |
| Sanofi-Aventis U.S. LLC | $171.00 | 2022 | |
| Sobi, INC | $125.00 | 2024 | |
| Fresenius Kabi USA, LLC | $122.54 | 2025 | Smoflipid |
| Philips North America LLC | $117.84 | 2024 | (1439) Hpm Undivided |
| Janssen Pharmaceuticals, INC | $108.95 | 2023 | Xarelto |
| Amgen INC. | $101.00 | 2025 | |
| Vapotherm INC | $85.99 | 2023 | Vapotherm |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Btg International INC. | $77.26 | 2024 | |
| Fresenius USA Marketing, INC. | $35.82 | 2024 | Nxstage System One |
| Abiomed | $14.34 | 2023 | Impella |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Menchaca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.